However, CX3CL1 levels in D3 lysates were increased when PBMCs from control patients (by 45.95-fold), mild AD patients (by 51.21-fold) and from moderate AD patients (by 42.00-fold) were in contact with the BBB model, compared to D3 in BBB without PBMCs (Table 2). This evidence concerns the gene CX3CL1 and Alzheimer disease.